Search results
Showing 16 to 30 of 36 results for everolimus
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
Drug-eluting stents for the treatment of coronary artery disease (TA152)
Evidence-based recommendations on using drug-eluting stents in adults.
Tivozanib for treating advanced renal cell carcinoma (TA512)
Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.
Discontinued [GID-TAG241]
Cabozantinib for untreated advanced renal cell carcinoma (TA542)
Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults.
Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]
Discontinued [GID-TAG232]
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
June 2013 TA219 Renal cell carcinoma (second line metastatic) - everolimus 28 February 2011 TA085 Renal transplantation -...
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Show all sections